GSK's VC unit SR One has new chief

There's some new blood at the helm of London-based drug giant GlaxoSmithKline's venture group. Jens Eckstein, previously a venture partner and entrepreneur-in-residence at TVM Capital, has jumped aboard as president of SR One. He takes over for biotech venture capitalist Christoph Westphal, who had been wearing multiple hats. Westphal ran the show at SR One while serving as a partner of his own VC group, Longwood Founders Fund, which has funding support from GSK, Genzyme and other sources. Eckstein, a biochemist by training, was a general partner focused on early stage life sciences investments before his role changed to venture partner and EIR earlier this year. Release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.